Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00920257 | A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795 | PHASE1 | COMPLETED | 77 | — | — | Jun 16, 2009 | Apr 17, 2013 | Nov 13, 2017 | 7 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| GSK2141795 | EXPERIMENTAL | Oral GSK214179 given daily to patients with cancer. Groups of approximately three patients will receive GSK2141795 at increasing doses until a maximum tolerated dose is identified. |
| Name | Type | Description |
|---|---|---|
| GSK2141795 | DRUG | GSK2141795 is an oral AKT inhibitor. |
Inclusion Criteria: * Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. * Male or female, 18 years or older. * Histologically or cytologically confirmed diagnosis of solid tumor malignancy or lymphoma that is not...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |